The latest news:

• Celldex vaccine improves long-term brain cancer survival in study         Amazing results.  25% of patients with recurrent gbm alive after 2 years compared with NONE in the control group!  The FDA should try to get this approved as soon as possible. We shouldn't have to wait years for another study.
  



• New Phase 3 Data show Optune in Combination with Second Line Chemotherapy is Superior to Second Line Chemotherapy Alone in Glioblastoma Patients at First Recurrence         This is a new report on combining Optune with Avastin. Both are approved for recurrent GBM. The combination reduced the chance of dying by 39% compared to Avastin alone.  This should be the standard for recurrent gbm and investigated for newly diagnosed.
  



• ImmunoCellular Therapeutics Ltd Presents Updated ICT-107 Phase 2 Survival and Immune Response Data at the Society for Neuro-Oncology Annual Meeting 2015         Good  news from the SNO meeting: Although they did not hit the original target of overall survival for all patients in the trial, they found a subgroup of patients where the vaccine worked very well. Newly diagnosed GBM patients with a blood type of HLA-A2+ did very well. If the MGMT methylation status was positive, there was a 58% increase in survival compared to the control group. If the MGMT status was negative, there was a 34% increase in survival.  This is for a treatment that is just a simple shot in the arm and once approved, could just be added to other treatments. They just started a new phase 3 trial that will require patients to be HLA-A2+.  This should show a big improval.
  



• IBTA E-News        From our good friends at the IBTA! 
  



• CURE Media Group’s Heroes of Glioblastoma Announced Today         Congratulations  to the four heroes!  
  

BrainTumor Co-Payment Assistance Program Status:

• OPEN to new applicants